Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 27

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 27
---
| (10) | Consists of (i) 24,991 common shares and (ii) 12,496 common shares issued as an equity award grant outside of the Plan.                                                                                                                                                                                              |
| (11) | Consists of 12,496 common shares issued as an equity award grant outside of the Plan.                                                                                                                                                                                                                                |
| (12) | Consists of 24,991 common                                                                                                                                                                                                                                                                                            
 shares as an equity award grant outside of the Plan.                                                                                                                                                                                                                                                                 |
| (13) | The address of Yehonatan Shachar is c/o Clearmind Medicine Inc., 101 – 1220 West 6th Avenue, Vancouver, British Columbia V6H1A5. Yehonatan Shachar is a member of our board of directors.                                                                                                                            |
| (14) | Consists of (i) 24,991 common shares and (ii) 12,496 common shares issued as an equity award grant outside of the Plan.                                                                                                                                                                                              |
| (15) | Consists of 12,496 common shares issued as an equity award grant outside of the Plan.                                                                                                                                                                                                                                |
| (16) | Consists of 24,991 common                                                                                                                                                                                                                                                                                            
 shares as an equity award grant outside of the Plan.                                                                                                                                                                                                                                                                 |
| (17) | The address of Alan Rootenberg is c/o Clearmind Medicine Inc., 101 – 1220 West 6th Avenue, Vancouver, British Columbia V6H1A5. Alan Rootenberg is our chief financial officer.                                                                                                                                       |
| (18) | Consists of 9,461 common shares issued as an equity award grant outside of the Plan.                                                                                                                                                                                                                                 |

<div align='center'>13

DESCRIPTION OF SHARE CAPITAL</div>

General

The following is a summary
of the material terms of our share capital, as set forth in our articles of association, as the same will be effective at the time of
the consummation of this offering, and certain related sections of the Business Corporations Act (British Columbia), or the BCBCA. The
following summary is subject to, and is qualified in its entirety by reference to, the provisions of our articles of association and the
applicable provisions of the BCBCA.

On September 30, 2022, our
shareholders approved a one-for-30 reverse split of our issued and outstanding common shares. In addition, on November 28, 2023, we effected
a one-for-30 consolidation